Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
ZLDPF Quote, Financials, Valuation and Earnings
Last price:
$77.05
Seasonality move
:
6.28%
Day range:
$75.24 - $77.05
52-week range:
$49.98 - $110.00
Dividend yield:
0%
P/E ratio:
5.54x
P/S ratio:
3.92x
P/B ratio:
2.27x
Volume:
1.7K
Avg. volume:
386
1-year change:
-23.02%
Market cap:
$5.4B
Revenue:
$9.1M
EPS (TTM):
$13.90
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Zealand Pharma A/S has -70.8% downside to fair value with a price target of -- per share.
ZLDPF vs. S&P 500
-
Over the past 5 trading days, Zealand Pharma A/S has underperformed the S&P 500 by -4.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Zealand Pharma A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zealand Pharma A/S has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Zealand Pharma A/S reported revenues of $7.8M.
Earnings Growth
-
Zealand Pharma A/S earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Zealand Pharma A/S reported earnings per share of -$0.90.
Enterprise value:
2.9B
EV / Invested capital:
1.20x
Price / LTM sales:
3.92x
EV / EBIT:
2.64x
EV / Revenue:
2.11x
PEG ratio (5yr expected):
-0.56x
EV / Free cash flow:
2.53x
Price / Operating cash flow:
4.71x
Enterprise value / EBITDA:
2.63x
Gross Profit (TTM):
$1.4B
Return On Assets:
51.81%
Net Income Margin (TTM):
71.79%
Return On Equity:
58.28%
Return On Invested Capital:
56.33%
Operating Margin:
-930.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $49.9M | $11.1M | $1.4B | $650.1K | $7.8M | |
| Gross Profit | $42.4M | $5.2M | $1.4B | $713.3K | $6.6M | |
| Operating Income | -$73.9M | -$161.8M | $1.1B | -$51M | -$72.2M | |
| EBITDA | -- | -- | $1.1B | -$50.1M | -$71.1M | |
| Diluted EPS | -$2.05 | -$2.42 | $13.90 | -$0.56 | -$0.90 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204.8M | $109.9M | $279.1M | $1.3B | $2.6B | |
| Total Assets | $258.8M | $143.8M | $308.9M | $1.4B | $2.6B | |
| Current Liabilities | $48.4M | $29.8M | $36.6M | $36.8M | $185.5M | |
| Total Liabilities | $74M | $95.5M | $50.9M | $111.8M | $257.3M | |
| Total Equity | $184.8M | $48.3M | $258M | $1.3B | $2.4B | |
| Total Debt | $22.1M | $65.3M | $16.5M | $58.3M | $64M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$107.8M | -$100.8M | $1.2B | -$43.5M | -$33M | |
| Cash From Investing | -$146.6M | -$1.1B | -$240.3M | -$894.5M | -$138.6M | |
| Cash From Financing | $236.7M | $1.2B | -$96.7M | -$40.1M | -$13.7M | |
| Free Cash Flow | -$110.7M | -$103.8M | $1.2B | -$43.6M | -$33.7M | |
ZLDPF
Sector
Market Cap
$5.4B
$28.1M
Price % of 52-Week High
70.05%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
1.82%
-1.49%
1-Year Price Total Return
-23.02%
-17.13%
Beta (5-Year)
0.720
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$76.13
200-day SMA
Buy
Level
$68.82
Bollinger Bands (100)
Buy
Level
63.25 - 79.95
Chaikin Money Flow
Buy
Level
2.9K
20-day SMA
Sell
Level
$78.20
Relative Strength Index (RSI14)
Sell
Level
49.52
ADX Line
Sell
Level
14.22
Williams %R
Neutral
Level
-36.751
50-day SMA
Buy
Level
$76.22
MACD (12, 26)
Buy
Level
18.54
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
738
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.5782)
Sell
CA Score
(Annual)
Level (-0.3086)
Sell
Beneish M-Score
(Annual)
Level (1.991)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.2281)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Stock Forecast FAQ
In the current month, ZLDPF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZLDPF average analyst price target in the past 3 months is --.
-
Where Will Zealand Pharma A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zealand Pharma A/S share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Zealand Pharma A/S?
Analysts are divided on their view about Zealand Pharma A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zealand Pharma A/S is a Sell and believe this share price will rise from its current level to --.
-
What Is Zealand Pharma A/S's Price Target?
The price target for Zealand Pharma A/S over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZLDPF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zealand Pharma A/S is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ZLDPF?
You can purchase shares of Zealand Pharma A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zealand Pharma A/S shares.
-
What Is The Zealand Pharma A/S Share Price Today?
Zealand Pharma A/S was last trading at $77.05 per share. This represents the most recent stock quote for Zealand Pharma A/S. Yesterday, Zealand Pharma A/S closed at $77.05 per share.
-
How To Buy Zealand Pharma A/S Stock Online?
In order to purchase Zealand Pharma A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ZLDPF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZLDPF
Sector
P/E ratio
5.54x
23.89x
PEG ratio
-0.56x
-0.01x
P/B ratio
2.27x
1.81x
Price / LTM sales
3.92x
1.59x
Growth Metrics
ZLDPF
Sector
Revenue growth
1093.82%
4.62%
Earnings growth
-62.16%
11.06%
Revenue (5-year growth)
7.97%
6.5%
Earnings forecast
--
-$0.21
Profitability
ZLDPF
Sector
Profitability FY 2024
$4.2M
$3.6M
Return on invested capital
56.33%
-31.84%
Return on assets
51.81%
-27.96%
Return on equity
58.28%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Feb
12
Balance Sheet
ZLDPF
Sector
Total cash
$2.5B
$26.4M
Short term investments
$1.1B
$25.7M
Total assets
$1.5B
$76.9M
Long term debt
$64M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
